Cancer claims over seven million lives every year and the number continues to rise. Every patient faces a life-altering journey which exerts a physical, emotional and financial strain on themselves, their families, and even the health systems. Biocon aims to transform cancer by delivering extraordinary and affordable targeted therapies that prolong and improve patients’ lives worldwide.

While our world-class cancer-care therapies, both biosimilars and novel biologics, have seen tremendous progress in the diagnosis and treatment of cancers over the last few decades, there is still a huge unmet need of a complete cure.

• BIOMAb EGFR® remains one of the most preferred targeted therapies in the treatment of head and neck cancers, for its excellent safety and efficacy profile.
• In addition to novel biologics, Biocon is addressing a large unmet need for advanced cancer medicines through high quality, affordable life-saving biosimilars such as Trastuzumab and Bevacizumab
• These therapies provide cost-effective alternatives to expensive reference biologics
• Biocon is also developing the first wave of biosimilars for global markets

• NUFIL™, an indigenously developed Filgrastim for the treatment of chemotherapy induced neutropenia
• Evertor™ for the treatment of advanced renal cell carcinoma. Developed indigenously using our proprietary technology, Evertor™ was India’s first generic everolimus.
• Trastuzumab, a targeted therapy for HER2-positive metastatic breast cancer.Known as CANMAb™, its affordability has helped expand the patient pool by four times and it is the most preferred biosimilar Trastuzumab brand in India.
• Trastuzumab launched in emerging markets including Brazil and Algeria Biocon was the first company globally to receive an approval from the U.S. Food and Drug Administration (FDA) in 2017.
• Ogivri™, co-developed with our partner Mylan, is also the first biosimilar to get regulatory approval in the U.S.
• Biocon was also the first to receive approval for a biosimilar, Pegfilgrastim, from the U.S. FDA in 2018.
• Fulphila™ (biosimilar pegfilgrastim), launched in the U.S. by Mylan, is helping patients with nonmyeloid cancers reduce the risk of infection following myelosuppressive chemotherapy.
• Fulphila™ is the first alternative and affordable treatment option to the innovator drug.
• Biocon launched its first biosimilar in India for various types of cancer.
• Bevacizumab, known as KRABEVA®, is our second Oncology Biosimilar in India after Trastuzumab and is prescribed for metastatic colorectal cancer (mCRC) and several other types of lung, kidney, cervical, ovarian and brain cancers.

Biocon’s contribution to bringing affordable oncology therapeutics to the Indian market has already made a significant impact in the realm of cancer care and is positioning us as a leading Oncology Company.